March 8, 2021
Managing Intellectual Property
By Daniele M. San Román; Kyu Yun Kim; Michele C. Bosch; M. Paul Barker; Thomas L. Irving
Innovative pharma has had three decisions from the US Court of Appeals for the Federal Circuit to cheer about recently: Sanofi v Watson in 2017, Vanda v West-Ward in 2018, and GSK v Teva in 2020.
Strategically-minded in-house and private practice counsel in the innovator pharma space should look to this trilogy of label-related rulings to help them create comprehensive patent prosecution and litigation strategies for their clients.
In this article, we will review each of these cases and discuss how they help the innovative pharma industry. With respect to GSK v Teva, we note that on February 9, 2021, the Federal Circuit withdrew the opinion we have discussed below and granted rehearing of the appeal on the merits.
Oral argument was held on February 23, 2021 – stay-tuned for the panel’s rehearing decision.
Click here to read the full article.
United States Court of Appeals for the Federal Circuit (CAFC), new drug application (NDA), Food and Drug Administration (FDA)
Originally printed in Managing Intellectual Property on March 8, 2021. This article is for informational purposes, is not intended to constitute legal advice, and may be considered advertising under applicable state laws. This article is only the opinion of the authors and is not attributable to Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, or the firm’s clients.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
10th Annual Georgia Asian Pacific American Bar Association Gala
May 29, 2024
Atlanta
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.